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Abstract
Background: Patient-ventilator asynchrony is a common problem in mechanically ventilated patients with acute
respiratory failure. It is assumed that asynchronies worsen lung function and prolong the duration of mechanical
ventilation (MV). Neurally Adjusted Ventilatory Assist (NAVA) is a novel approach to MV based on neural respiratory
center output that is able to trigger, cycle, and regulate the ventilatory cycle. We hypothesized that the use of
NAVA compared to conventional lung-protective MV will result in a reduction of the duration of MV. It is further
hypothesized that NAVA compared to conventional lung-protective MV will result in a decrease in the length of
ICU and hospital stay, and mortality.
Methods/design: This is a prospective, multicenter, randomized controlled trial in 306 mechanically ventilated
patients with acute respiratory failure from several etiologies. Only patients ventilated for less than 5 days, and who
are expected to require prolonged MV for an additional 72 h or more and are able to breathe spontaneously, will
be considered for enrollment. Eligible patients will be randomly allocated to two ventilatory arms: (1) conventional
lung-protective MV (n = 153) and conventional lung-protective MV with NAVA (n = 153). Primary outcome is the
number of ventilator-free days, defined as days alive and free from MV at day 28 after endotracheal intubation.
Secondary outcomes are total length of MV, and ICU and hospital mortality.
Discussion: This is the first randomized clinical trial examining, on a multicenter scale, the beneficial effects of
NAVA in reducing the dependency on MV of patients with acute respiratory failure.
Trial registration: ClinicalTrials.gov website (NCT01730794). Registered on 15 November 2012.
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Background
The act of taking a breath is controlled by the respiratory
center of the brain, which decides the characteristics of
each breath, its timing, and its size. The respiratory center
sends a signal along the phrenic nerve that excites the dia-
phragmatic muscle cells, leading to muscle contraction
and descent of the diaphragmatic dome. As a result, the
pressure in the airway drops causing an inflow of air into
the lungs. Patient-ventilator asynchrony is a common
problem in mechanically ventilated patients with acute re-
spiratory failure (ARF). Asynchrony has been frequently
documented in both volume and pressure assist/control
(A/C) as well as pressure support ventilation. Two recent
clinical studies have reported an increased length of
mechanical ventilation (MV) requirement in patients
with an Asynchrony Index (AI) ≥ 10 % versus those with
an AI < 10 %. AI is defined as the ratio between number of
asynchronies per minute/total respiratory rate × 100. In
one study, patients with an AI ≥ 10 % required 25.5 days
of ventilatory support versus 7.5 days in those with an
AI < 10 % [1], while in the other study the number of
ventilator-free days (VFDs) was 21 days (AI ≥ 10 %) ver-
sus 25 (AI < 10 %) [2]. In a more recent study in 50 pa-
tients all triggering the ventilator, every patient had
multiple periods during the day where the AI was over
5 % and some had an AI as high as 40 % [3]. Of even
greater concern is the fact the clinicians have a very dif-
ficult time identifying the presence of asynchrony and
determining the AI at the bedside [4].
A new mode of ventilation, Neurally Adjusted Ventila-
tory Assist (NAVA) has been recently introduced [5–16].
With NAVA, the electrical activity of the diaphragm
(Edi) is captured, fed to the ventilator and used to assist
the patient’s breathing in synchrony with, and in propor-
tion to, the patient’s own efforts regardless of patient
category or size. NAVA triggers, cycles and regulates gas
delivery based on the diaphragmatic electromyography
(EMG) signal via a specially designed nasogastric tube
(Edi). As the work of the ventilator and the diaphragm is
controlled by the same signal, coupling between the dia-
phragm and the ventilator is synchronized simultaneously.
As a result, synchrony should be markedly improved with
NAVA since neither air leaks nor auto-positive end-
expiratory pressure (auto-PEEP) should affect the ability
of the ventilator to trigger, deliver gas or cycle.
We hypothesized that the use of NAVA will improve
patient-ventilator interaction, will make the transition to
spontaneous breathing much quicker and easier, and will
result in an increase in VFDs in patients with ARF when
compared to conventional lung-protective MV. If our
hypothesis is correct, the use of NAVA will decrease the
duration of MV, the length of intensive care unit (ICU)
stay, ventilator-associated complications, and has the po-
tential to increase overall survival of patients with ARF.
Methods/design
Justification of the study
Patient-ventilator asynchrony is a common problem in
mechanically ventilated patients with ARF who are re-
ceiving assisted ventilation. Based on new data, all pa-
tients managed with conventional modes of MV have an
AI > 5 % at various points during the day [3]. NAVA is a
unique approach to MV based on neural respiratory out-
put, providing a smooth transition to natural breathing.
NAVA better assures that the patient’s breathing is in
synchrony with, and in proportion to, the patient’s own
efforts, regardless of patient category or size.
We justify the need for our study based on the fact
that NAVA can provide a smooth transition to natural
breathing. We hypothesized that the use of NAVA com-
pared to conventional lung-protective MV will result in
a decrease in the number of days of MV. It is further hy-
pothesized that NAVA will result in a decrease in the
length of ICU and hospital stay. The goal of this study is
to compare the ability of NAVA versus conventional
lung-protective MV to provide invasive ventilatory sup-
port during ARF in adults who are expected to require
ventilatory support for at least 72 h.
Study design
This study is a prospective, multicenter, randomized
controlled, clinical trial in 306 adult patients (male and
female) with ARF admitted to a network of 18 ICUs from
university and community hospitals in Spain (Appendix 1).
The trial has been designed in accordance with the
fundamental principles established in the Declaration
of Helsinki, the Convention of the European Council
related to human rights and biomedicine, and the
Universal Declaration of UNESCO on the human gen-
ome and human rights, and within the requirements
established by the Spanish legislation (Law 14/2007, Law
15/1999) in the field of biomedical research, the protec-
tion of personal data, and bioethics. The study was regis-
tered on 15 November 2012 at https://clinicaltrials.gov/
ct2/show/NCT01730794 with the identification number
NCT01730794. The study was approved by a referral
Ethics Committee (Hospital Clínico Universitario de
Valencia, Valencia, Spain) and the Institutional Review
Boards (IRBs) of all participating hospitals (Additional
file 1). For inclusion into the study, signed written
informed consent from the patient or the patient’s
personal legal representative will be obtained (Additional
file 2). See Additional file 3 for the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) checklist of the study protocol.
Study population
To be eligible for inclusion into this study (day 0), each
patient must fulfill the following inclusion criteria during
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screening and prior to enrollment into the trial: be aged
18 years or older, have hypoxemic or hypercapnic ARF,
be intubated and mechanically ventilated for less than
5 days but expected to be ventilated for at least 72 h,
and be able to spontaneously trigger the ventilator. Pa-
tients will be excluded from study participation if any of
the following criteria are present: moderate or severe acute
respiratory distress syndrome (ARDS) [17], the presence
of three or more organ system failures, require noninva-
sive ventilation, be unable to spontaneously breathe, or
have a poor short-term prognosis (defined as a high risk of
death in the next 3 months), neuromuscular or neuro-
logical disease, lack of informed consent, and any medical/
surgical contraindication.
Enrollment into the study and randomization
Although the calculation of AI is not mandatory for
patient enrollment after patient consent, it is recom-
mended to perform (and save) a 1- to 15-min tracing re-
cording of the patients’ pressure and flow waveforms
during the mode of MV that they were receiving at the
time of randomization. At the end of the study, in a ran-
domly selected 10 % of enrolled patients, the AI will be
calculated based on the following: (1) number of missed
triggers (an airway pressure decrease of at least 0.5
cmH2O that does not result in triggering of the ventilator),
(2) number of double triggers (two consecutive breaths
without an exhalation between them), (3) auto-triggers
(ventilator triggering to inspiration without a decrease in
airway pressure of at least 0.5 cmH2O), (4) short inspira-
tory time (inspiratory time less than half of the mean in-
spiratory time), and (5) long inspiratory time (inspiratory
time more than twice the mean inspiratory time). We will
determine the AI using the formula from Thille et al. [1]:
AI %ð Þ ¼ number of asynchrony events=total respiratory rate
which includes ventilatory cycles þ wasted effortsð Þ  100:
Thille et al. placed a pressure transducer and pneumo-
tachograph at the airway and recorded breaths for
30 min. This is impractical to do as an entry criterion
for a multicenter randomized controlled trial. However,
all possible efforts will be made to record representative
waveform tracings using the Servo-tracker software, or
the Servo-i ventilator PCMCIA recording cards, or by
any other means during a 1- to 15-min period of the
ventilatory tracing before enrollment.
Eligible and informed consented patients who are ex-
pected to be ventilated for at least 72 h will be enrolled
and randomly allocated to two arms: (1) NAVA or (2)
conventional lung-protective MV, within the first 5 days
(120 h) after endotracheal intubation (Fig. 1).
The randomization list was done by the statistician of
the study (MAGB), according to a computer-generated
random number table based on a 1:1 allocation. This list
was generated when the investigators and all Ethics
Committees and IRBs of the participating centers had
approved the study design. Randomization is stratified
by center to ensure an equal distribution of patients in
each arm by each ICU. Patients are randomly allocated
to the two arms of the study (NAVA or no NAVA) by
the clinical investigator in each participating ICU ac-
cording to the precise written allocation contained inside
a prenumbered, opaque, sealed envelope sent in blocks
of ten envelopes to each participating ICU. Investigators
must respect the numerical sequence of the envelopes.
Only two members of the Trial Management Team have
access to the randomization list: the project manager
and the statistician. They keep the randomization list in
their private office at the Research Unit of the Coordin-
ating Center. The coordinating center does not enroll
patients.
Our study characteristics do not allow the blinding of in-
vestigators to the intervention being tested. Once a partici-
pating ICU randomizes a patient, their investigators must
contact the project manager of the study to inform and
confirm the randomization number, the correct sequence
of the prenumbered envelope, and the intervention arm.
Screening, enrollment, randomization, treatment initiation,
and follow-up of randomized patients is performed by the
investigators and attending physicians in each participating
ICU. Subsequent blocks of ten envelopes are sent to those
participating ICUs with high enrollment rates. Participating
clinicians do not know whether the pattern of stratification
by center is for every 10, 20, or more envelopes during the
study period.
Ventilatory management
In the conventional lung-protective MV group, patients
will be ventilated using either volume assist/control (A/C),
pressure A/C, pressure support (PS), pressure-regulated
volume control (PRVC), or volume support (VS) at the
discretion of the medical team with tidal volumes (VT) in
the 4 to 8 ml/kg predicted body weight (PBW) range and
plateau pressure or pressure (control or support) level
Fig. 1 Study design diagram
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setting of 30 cmH2O or less. During A/C the backup rate
must be set to insure that more than 90 % of breaths are
triggered by the patient. In the weaning phase of ventila-
tory support, a VT of up to 10 ml/kg will be acceptable.
Volume and pressure ventilation should be optimized by
careful adjustment of peak flow and inspiratory time
(volume ventilation), and rise time and termination criteria
(pressure ventilation) to insure maximum patient-ventilator
synchrony. In volume ventilation, inspiratory time should
be less than 1.0 s and peak flow should be high enough to
avoid any concavity during the initial part of inspiration. In
pressure ventilation, rise time should also be set to avoid
any concavity during the initial part of inspiration, and the
patient’s neural inspiratory time and the ventilator’s inspira-
tory time should end simultaneously by careful setting of
inspiratory time or termination criteria. Trigger sensitivity
should be set to insure the minimal effort that does not re-
sult in auto-triggering.
For the purpose of this study, patients allocated to the
NAVA group will be ventilated with Servo-i ventilators
(Maquet-Getinge, Solna, Sweden). One NAVA catheter
size will be used for this study: Edi catheter 16 Fr
(Maquet-Getinge, Solna, Sweden). For details on guidelines
for positioning the Edi Catheter, initial NAVA settings, and
subsequent adjustments of NAVA, see Additional file 4.
The NAVA level will be set initially at zero, then the
maximum Edi will be determined as the average level
over the next at least three to five breaths without ven-
tilatory support but with 5 cmH2O of PEEP. The actual
NAVA level will then be titrated by the clinician to
achieve the following: (1) an Edi equal to approximately
50 % of the maximum Edi, (2) an average VT of between 4
to 8 ml/kg PBW, and (3) an average respiratory rate of be-
tween 15 and 40 per min. In addition, the trigger sensitiv-
ity should be set as sensitive as possible without causing
auto-triggering and the maximum pressure limit in NAVA
should be set at 40 cmH2O. The NAVA catheter should be
changed every 5 days.
In both groups, PEEP will be set in hypoxemic ventila-
tory failure patients at a minimum of 5 cmH2O. Since
none of these patients will have moderate or severe
ARDS, it is expected that PEEP levels in most patients
will be set between 5 and 15 cmH2O based on the clin-
ical judgment of the attending physician. The primary
exception to this is patients with marked obesity who
may require PEEP levels of up to 15 to 20 cmH2O. How-
ever, a high-PEEP-low-FiO2 approach is expected with
all of these patients. In chronic obstructive pulmonary
disease (COPD) patients, PEEP will be set to offset auto-
PEEP. That is, PEEP will be increased to the level that
insures that the vast majority of patient efforts result in
triggering of the ventilator. In congestive heart failure
patients, PEEP will be set at 8 to 12 cmH2O based on
the patient’s hemodynamic status.
In both arms, FiO2 will be set to insure a PaO2 of 60
to 80 mmHg after the setting of PEEP. In patients who
leave the ICU for any reason, the randomized approach
should be continued during their travel. Patients who re-
quire sedation or anesthesia for procedures should be
placed back on the appropriately randomized mode as
soon as they are able to breathe spontaneously. Through-
out this study, the applied VT will be based on the pa-
tients’ PBW. The following formulas are to be used to
calculate PBW (kg):
PBW ¼ 50:0 þ 0:91  height in cm − 152ð Þ½  for men;
and
PBW ¼ 45:5 þ 0:91  height in cm − 152ð Þ½  for women:
In all patients, weaning will be performed by a spon-
taneous breathing trial (SBT) [18]. Following extubation
in both groups, noninvasive ventilation will be applied
for 24 to 48 h if patients are over 65 years old, have
COPD or congestive heart failure, have an ineffective
cough and excessive secretions, have had at least one
weaning failure, more than one comorbid condition,
upper airway obstruction, or an APACHE II score > 12
on the day of extubation. In the control arm noninvasive
PS will be applied, and in the NAVA arm noninvasive
NAVA will be applied.
If, after 2 h post extubation, an FiO2 > 0.40 is required,
patients will be maintained on continuous positive airway
pressure (CPAP) at 10 cmH2O or bilevel positive airway
pressure (BiPAP) at clinically determined settings with
peak inspiratory pressure of 20 cmH2O or less via face
mask until they are able to maintain a PaO2 > 60 mmHg
on an FiO2 ≤ 0.40. If patients do not respond to CPAP/
BiPAP within 2 h, reintubation for those considered failing
should not be delayed. Patients in the NAVA group should
not have the NAVA catheter removed until BiPAP or
CPAP has been discontinued. If these patients are reintu-
bated they are to return to NAVA.
Daily spontaneous breathing trial (SBT) assessment/
performance for both groups
Prior to the start of a SBT the patient should demonstrate:
(1) a partial reversal of the underlying cause of ARF, (2)
SpO2 ≥ 88 % or PaO2 ≥ 55 mmHg with FiO2 ≤ 0.40 and
PEEP of 8 cmH2O or less, (3) hemodynamic stability, (4) a
level of sedation appropriate for SBT, and (5) the ability to
spontaneously breathe.
The SBT will be conducted for 30 to 60 min. The SBT
should be conducted while attached to the ventilator
with the ventilator set at zero or 5 cmH2O pressure sup-
port and zero or 5 cmH2O of CPAP or via a T-piece
with the same FiO2 as during ventilation. Any of the fol-
lowing criteria identify failure of the SBT: (1) respiratory
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rate (RR) ≥ 35/min for 5 min or longer, (2) sustained
SpO2 < 88 %, (3) mean arterial pressure sustained < 60
or > 120 mmHg, (4) ischemic changes on the electrocar-
diogram, (5) new onset of paradoxical breathing, accessory
muscle use, nasal flaring, etc., and (6) agitation, diaphor-
esis, anxiety that does not resolve with reassurance. Those
patients successfully completing a 30- to 60-min SBT
will be extubated unless there is a specific reason not
to extubate. The reason for not extubating a patient
after a successful SBT will be documented.
General care and procedures for both groups of patients
All participating patients, regardless of the study arm
into which they are randomized, will be monitored and
managed following general standard of care practices
aimed at maintaining optimal conditions. Measurement
of auto-PEEP (the static end-expiratory pressure follow-
ing an end-expiratory pause of at least 2.0 s) and meas-
urement of plateau pressure (the static end-inspiratory
pressure following an end-inspiratory pause of at least
2.0 s) will be performed daily as needed. Active humidi-
fication or heat and moisture exchangers (HMEs) may
be used on patients on either group. Mechanical dead
space will be minimized on all patients. Use of inline
suction catheters is up to the discretion of the investigator;
however, they are recommended in all patients. Normal
body temperature will be maintained. Ventilator circuits
and inline suction catheters do not need to be changed on
a regular basis. During airway suctioning the following will
be avoided: instillation of saline, manual ventilation, and
aggressive suction. Suctioning will only occur when secre-
tions are present; routine suctioning should be avoided.
Ideally metered-dose inhalers (MDIs) or Aerogen nebu-
lizers should be used for aerosol therapy. A spacer should
be maintained in the inspiratory limb. If a small volume
nebulizer is used, a one-way valve T-piece will be used
to avoid disconnection of the circuit. Correction for
compressible volume of the circuit will be activated in
all patients regardless of arm of the study.
Minimal sedation and appropriate analgesia will be
maintained in all patients. The sedative/analgesic regimen
and dose will be those selected by the managing physician
at all times according to the needs of the patient and unit
policies. Sedation should be titrated according to any of
the commonly used sedation scales: the Riker Sedation-
Agitation Scale (SAS) [19], the Ramsay Sedation Scale
[20], or the Richmond Agitation Scale (RASS) score [21]
(see Additional file 4). Appropriate analgesia will be given
so that no more than minimal sedation will be necessary.
The specific drugs used and dosing regimen will be left up
to the individual investigator. Drugs used and dose per kg
will be recorded on the data forms.
When an appropriate fluid challenge fails to restore
adequate blood pressure and organ perfusion, therapy
with vasopressor agents should be started. Either nor-
epinephrine or dopamine (through a central catheter as
soon as available) is the first-choice vasopressor agent to
correct hypotension in septic shock. Vasopressin may be
considered in patients with refractory shock despite ad-
equate fluid resuscitation and high-dose conventional
vasopressors. These recommendations may be revised as
the new surviving sepsis guidelines become available. In
patients with low cardiac output despite adequate fluid
resuscitation, dobutamine may be used to increase cardiac
output. If used in the presence of low blood pressure it
should be combined with vasopressor therapy. A strategy
of increasing Cardiac Index to achieve an arbitrarily prede-
fined elevated level is not recommended.
Enteral nutrition should be provided as soon as it is
deemed safe by the treating physicians. Exogenous insu-
lin should be provided with the goal of achieving a blood
glucose level below 150 mg/dl for the first 3 days of crit-
ical illness. If, after 3 days, enteral nutrition has been
established and other resuscitation measures have been
provided, a goal of normoglycemia (110–140 mg/dl) should
be considered. This approach should minimize the poten-
tial impact of hypoglycemia. Ongoing randomized con-
trolled trials may change these recommendations, in which
case we will provide protocol amendments if necessary.
Data on lung mechanics, gas exchange, and
hemodynamics will be gathered before applying study
settings, then after applying study settings at times 0,
4 h, 24 h, 48 h, 96 h, 7 days, 10 days, 14 days, and every
7 days thereafter and on the last day of invasive ventilatory
support (Table 1). At initiation of the protocol and at 4 h,
data collected will represent one point in time, that is indi-
vidual data will be coupled. However, each day after that
data will not be coupled since the highest and lowest value
for each variable will be recorded. It is expected that this
data will be collected between 8 a.m. and 12 noon each
day. Also, at this time the maximum Edi (the peak inspira-
tory value) will be reassessed and readjustments of MV
will be made if necessary. Patients will be followed-up
(alive or dead) until ICU discharge. In addition, we will
record hospital length of stay and mortality.
Primary and secondary outcomes
The primary outcome of interest is the number of VFDs,
defined as days alive and free from MV at day 28 from
the onset of MV and from the day of randomization. For
subjects ventilated for 28 days or more and for subjects
who die, VFDs is 0. The secondary outcomes of interest
include: length of invasive MV, length of post-extubation
noninvasive ventilation, total assisted VFDs (invasive
plus noninvasive), length of ICU and hospital stay, and
ICU and hospital mortality, development of extrapulmon-
ary organ failure (any organ failure developed during the
study that was not present at the time of enrollment into
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the study) [22], prevalence of barotrauma (defined as the
presence of any extrapulmonary air that was not present
at study enrollment), ventilator-associated pneumonia (de-
velopment of a pneumonia 48 h after study entry), devel-
opment of ARDS after enrollment into the study, as
defined by the American-European Consensus Conference
(AECC) criteria for ARDS [23] or as moderate/severe
ARDS by the Berlin criteria [17], and time from first SBT
to extubation.
Sample size calculations and interim analysis
It is anticipated that the average patient with asynchrony
who is enrolled into this trial will have 21 VFDs with a
standard deviation (SD) of 6 VFDs, based on data from
Wit et al. [2]. Considering the impact of improved syn-
chrony on length of MV, we anticipate that NAVA will
increase VFDs by 2 days. No patient loss has been consid-
ered. We will only analyze patients who are enrolled and
randomized. The power analysis has been performed ac-
cording to Schoenfeld et al. [24]. Thus, the sample size
with an alpha of 0.05 and a beta of 0.2 (80 % power) is 153
patients in each group or a total of 306 patients requiring
randomization.
Interim analysis will be performed at hospital discharge
of the first 102 and 204 randomized patients. If, at the
time of these analyses, there is a trend toward better
outcome in the control group (p < 0.1) the study will be
terminated. The study will continue to randomize 306
patients if no adverse impact of the NAVA group is ob-
served. The interim analysis will be performed at the
coordinating center (Hospital Universitario Dr. Negrin,
Las Palmas de Gran Canaria, Spain) by an independent
Data and Safety Monitoring Board (DSMB). It is expected
that DSMB meetings will be by conference call and DSMB
discussions by email or conference call.
All adverse events reported will be sent to the DSMB
as well as to the IRB for review (see Additional file 4).
All serious events will be sent within 24 h after being re-
ceived by the coordinating center. Nonserious events will
be sent within 1 week of reception by the coordinating
center. All unexpected, and related or possibly related, ad-
verse events will be reported to the DSMB and the IRB.
The DSMB will review the overall status of the study:
number of patients enrolled overall and in each center, ad-
herence to the protocol overall and by each center.
Data analysis
Data will be collected in each participating ICU using a
standardized form. Data will be transmitted to the coord-
inating center whenever a patient dies or is discharged
from the hospital. Before exporting the data into a com-
puterized data base at the coordinating center, a trained
data collector from the coordinating center will check the
completeness and the quality of information. Logical
checks will be performed for missing data and to find in-
consistencies, especially regarding clinical diagnosis, date,
and ventilatory parameters. If necessary, the data collector
will contact the investigator by phone to validate the data
or reformat the data for entry into the database.
Descriptive statistics will be expressed as mean ± SD
or median and interquartile range depending on the na-
ture and distribution of the variables. Inferential statis-
tics will use estimates of the mean of the differences
and their 95 % confidence intervals (CI). Variables nor-
mally distributed will be compared with the Student’s t
test. For variables without a normal distribution, the
Mann-Whitney U rank test will be used for comparison.
Table 1 Schedule of events
Events Screening Day Randomization (Day 0) Day 1 Day 2 Day 3 Day 7 Day 10 Last day on MV
Study procedures
Informed consent form X
Medical history X X X X X X X X
Demographics X
Intervention
Treatment/intervention X X X X X X X
Blood chemistry
Blood gases X X X X X X X X
Efficacy measure
Lung mechanics X X X X X X X X
NAVA levels X X X X X X X X
Hemodynamic data X X X X X X X X
Radiological tests
Chest X-ray X X X X X X X X
MV mechanical ventilation, NAVA Neurally Adjusted Ventilatory Assist
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Categorical variables will be compared using Fisher’s exact
test. The primary outcome variable (number of VFDs) will
be assessed with the Student’s t test or the Mann-Whitney
U rank test dependent on the distribution of the data. The
relative risks and their 95 % CIs will be estimated. For all
these comparisons, we will consider a difference to be sta-
tistically significant if p < 0.05.
Discussion
Assisted MV is a highly complex process that requires
an intimate interaction between the ventilator and the
patient [25]. The complexity of the interaction between
the ventilator and the patient with ARF is frequently un-
derappreciated by the bedside clinician. The pattern of
gas delivery by the ventilator and the patient’s own
breathing pattern must match almost perfectly to avoid
asynchrony between the patient and the ventilator. To
date, we have no direct evidence that improving patient-
ventilator synchrony improves patient outcome. However,
there is growing evidence that asynchronies negatively cor-
relate with clinical outcomes, including prolonged MV and
ICU length of stay [1, 2] and lead to higher mortality [3].
NAVA is a newer mode for managing patients with
ARF under MV. The insertion of the NAVA catheter is
similar to the insertion of a nasogastric feeding tube and
it is not associated with any additional risks. Patients
with ARF who are able to breathe spontaneously while
they are receiving MV are required to follow the lead of
the ventilator and to adjust their respiratory center out-
put to match the way the clinician sets the ventilator,
otherwise, asynchrony will occur. Currently, it has be-
come more accepted that the respiratory center of the
patient in most circumstances is the most appropriate
determinant of ventilatory pattern as a result of the in-
creased recognition of the negative outcomes associated
with patient-ventilator asynchrony [3]. In a recent study,
Yonis et al. [26] reported reduced asynchrony during
assisted ventilation with NAVA as compared to pressure
support ventilation in 30 patients with respiratory failure
who were randomly assigned to 23 h of pressure support
ventilation and 23 h of NAVA. Also, in a previous study
[27], we reported that NAVA, as compared to pressure
support ventilation, resulted in improved synchrony,
reduced ventilatory drive, increased breath-to-breath
mechanical variability and improved patient comfort in
12 mechanically ventilated pediatric critically ill pa-
tients. In a series of 11 patients recovering from ARF,
NAVA provided better patient-ventilator interaction
[28]. In a recent study in 25 patients previously venti-
lated with controlled MV for at least 72 h who were
randomized to be ventilated for 48 h with pressure sup-
port ventilation (n = 12) or NAVA (n = 13), NAVA im-
proved diaphragmatic efficiency whereas pressure support
ventilation did not [29].
Since NAVA does not control the patient’s ventilatory
pattern, the patient is allowed to select whatever pattern
the respiratory center considers appropriate. Neither
pressure, flow, volume nor time is set by this novel ven-
tilatory modality of assisted MV. All that is set during
NAVA is the proportion of effort provided by the venti-
lator to supplement the patient’s own effort. In other
words, NAVA follow the lead of the patient but does not
force a ventilatory pattern on them [25]. If our hypoth-
esis is correct, the introduction of NAVA into the rou-
tine care of adult patients with ARF will have a marked
impact on the duration of MV, length of stay in critical
care units, and health care costs. If our hypothesis is
true, NAVA will become the preferred mode of assisted
MV in patients spontaneously breathing with ARF.
Trial status
The first patient was enrolled on 28 March 2014. The
expected duration of the study is 50 months.
Trial organization
The study principal investigators who contributed to the
study design and approved the final protocol constitute
the Steering Committee (Appendix 2). The Executive
Committee comprises the main investigators of each
participating center and is responsible for administrative,
trial, and data management. The Data and Safety Moni-
toring Board is composed of three external, independent
experts in critical care medicine, mechanical ventilation
and ARDS and, with the general data provided by three
internal members, it will recommend the continuation
or discontinuation of the trial based on the data from
the interim analysis. The Trial Management Team com-
prises a chief investigator, a project manager, a statisti-
cian, a clinical epidemiologist, and an investigator expert
in clinical trials. The responsibilities of this team are:
1. Planning and conducting the study: designing the
protocol, Case Report Forms, designing the
investigator manual, and managing and controlling
the data quality
2. Research center support: assisting the centers with
the administrative submission, monitoring
recruitment rates, providing sealed randomization
envelopes, taking actions to increase patient
enrollment, monitoring follow-up, auditing, and
sending study materials to the research centers
3. Producing a monthly study newsletter (Navanews)
4. Programming a Research-in-Progress meeting at
least once every year with the principal investigators
from all sites
5. Statistical analysis and research reporting: interim
and complete statistical analysis and helping to write
the final manuscript
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Appendix 1
NAVIATOR Network Investigators (in alphabetic order by
hospitals)
Isabel Murcia (Hospital General de Albacete, Albacete,
Spain); Javier Blanco, Luís Yuste, and María Carmen
Espinosa (Hospital General de Ciudad Real, Ciudad Real,
Spain); Carlos Ferrando, Marina Soro, Javier Belda, and
José Ferreres (Hospital Clínico Universitario de Valencia,
Valencia, Spain); Jesús Villar, Rosa Lidia Fernández, and
Miguel Ángel García-Bello (Hospital Universitario Dr.
Negrin, Las Palmas de Gran Canaria, Spain); César Pérez
Calvo and Anxela Vidal (Hospital Universitario Fundación
Jiménez Díaz, Madrid, Spain); Juan Alfonso Soler and Lucía
Capilla (Hospital Universitario Morales Meseguer, Murcia,
Spain); Raquel Montiel, Dácil Parrilla, Santiago Lubillo,
and Lina Pérez-Méndez (Hospital Universitario NS de
Candelaria, Santa Cruz de Tenerife, Spain); Francisco Alba
and Ruth Corpas (Hospital General NS del Prado, Talavera
de la Reina, Toledo, Spain); José Rubio (Hospital Puerta del
Mar, Cádiz, Spain); David Pestaña, Nilda Martínez, Ángel
Candela, and Pilar Cobeta (Hospital Universitario Ramón y
Cajal, Madrid, Spain); Lorena Fernández, Jesús Blanco,
César Aldecoa, and Jesús Rico (Hospital Universitario Río
Hortega, Valladolid, Spain); Ana San Sebastián Hurtado
and Marianela Hernández (Hospital Universitario de
Txagorritxu, Vitoria, Spain); Domingo Martínez, Luis A.
Conesa and Manuel Alfonso García (Hospital Universitario
Virgen de Arrixaca, Murcia, Spain); José Manuel Añón,
Elena González and Rosario Solano (Hospital Virgen de la
Luz, Cuenca, Spain); María Mar Cruz-Acquaroni and
María Ángela Magro-Martín (Hospital Virgen de la
Salud, Toledo, Spain); Robert M Kacmarek (Massachusetts
General Hospital, Boston, MA, USA).
Appendix 2
Steering Committee: Jesús Villar, Javier Belda, Fernando
Suárez-Sipmann, José Manuel Añón, Jesús Blanco, Lina
Pérez-Méndez, and Robert M. Kacmarek.
Data and Safety Monitoring Board: Pedro de la Oliva,
Paolo Pelosi, Lorenzo Berra (external members); Robert M
Kacmarek, Rosa L Fernández, and Jesús Villar (internal
members).
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